J Pathol Transl Med.  2017 Jul;51(4):388-395. 10.4132/jptm.2017.03.19.

Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients

• Kim SJ
• An S
• Lee JH
• Kim JY
• Song KB
• Hwang DW
• Kim SC
• Yu E
• Hong SM

• KMID: 2392579
• DOI: http://doi.org/10.4132/jptm.2017.03.19

Abstract

BACKGROUND
Pancreatic neuroendocrine tumors (PanNETs) are the second most common pancreatic neoplasms and there is no well-elucidated biomarker to stratify their detection and prognosis. Previous studies have reported that progesterone receptor (PR) expression status was associated with poorer survival in PanNET patients.
METHODS
To validate previous studies, PR protein expression was assessed in 21 neuroendocrine microadenomas and 277 PanNETs and compared with clinicopathologic factors including patient survival.
RESULTS
PR expression was gradually decreased from normal islets (49/49 cases, 100%) to neuroendocrine microadenoma (14/21, 66.6%) to PanNETs (60/277, 21.3%; p < .001). PanNETs with loss of PR expression were associated with increased tumor size (p < .001), World Health Organization grade (p = .001), pT classification (p < .001), perineural invasion (p = .028), lymph node metastasis (p = .004), activation of alternative lengthening of telomeres (p = .005), other peptide hormonal expression (p < .001) and ATRX/DAXX expression (p = .015). PanNET patients with loss of PR expression (5-year survival rate, 64.1%) had significantly poorer recurrence-free survival outcomes than those with intact PR expression (90%) by univariate (p = .012) but not multivariate analyses. Similarly, PanNET patients with PR expression loss (5-year survival rate, 76%) had significantly poorer overall survival by univariate (p = .015) but not multivariate analyses.
CONCLUSIONS
Loss of PR expression was noted in neuroendocrine microadenomas and was observed in the majority of PanNETs. This was associated with increased grade, tumor size, and advanced pT and pN classification; and was correlated with decreased patient survival time by univariate but not multivariate analyses. Loss of PR expression can provide additional information on shorter disease-free survival in PanNET patients.

Keyword

Pancreas; Neuroendocrine tumors; Receptors, progesterone; Survival

MeSH Terms

Carcinogenesis*
Classification
Disease-Free Survival
Humans
Lymph Nodes
Multivariate Analysis
Neoplasm Metastasis
Neuroendocrine Tumors*
Pancreas
Pancreatic Neoplasms
Progesterone*
Prognosis
Receptors, Progesterone*
Survival Rate
Telomere
World Health Organization
Progesterone
Receptors, Progesterone

Figure

• 

  Fig. 1. Representative images of progesterone receptor (PR) labeling in normal pancreas, neuroendocrine microadenoma, and pancreatic neuroendocrine tumor (PanNET). (A) Islets are positive, while acinar and ductal epithelial cells are negative for PR staining in the normal pancreas. Some neuroendocrine microadenomas show intact PR labeling (B), while other neuroendocrine microadenomas demonstrate loss of PR labeling (C). Some PanNETs show intact PR labeling (D), while other PanNETs demonstrate loss of PR labeling (E).

• 

  Fig. 2. Progesterone receptor (PR) expression status and the H-score in normal islets, neuroendocrine microadenomas, and pancreatic neuroendocrine tumors (PanNETs). (A) Comparison of PR expression in normal islets, neuroendocrine microadenomas, and PanNETs. (B) The H-score for PR in normal islets, neuroendocrine microadenomas, and PanNETs is 5.1±2.3, 3.0±3.3, and 1.3±2.5, respectively (p<.001).

• 

  Fig. 3. Kaplan-Meier survival analyses of pancreatic neuroendocrine tumor (PanNET) patients according to progesterone receptor (PR) expression. (A) The 100% overall 5-year survival rate for PanNET patients with PR expression is significantly better than that for those without insulin expression (76%, p=.015). (B) The recurrence-free 5-year survival rate for PanNET patients with PR expression (90%) is significantly better than that for those without PR expression (64.1%, p=.012).

Reference

1. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. 4th ed. Lyon: IARC Press;2010.

2. Picard F, Wanatabe M, Schoonjans K, O'Malley BW, Auwerx J. Progesterone receptor knockout mice have an improved glucose homeostasis secondary to beta -cell proliferation. Proc NatlAcad Sci USA. 2002; 99:15644–8.

3. Gastrointestinal Pathology Study Group of Korean Society of Pathologists, Cho MY, Kim JM, et al. Current trends of the incidence and pathological diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Korea 2000-2009: multicenter study. Cancer Res Treat. 2012; 44:157–65.

4. Bilimoria KY, Talamonti MS, Tomlinson JS, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008; 247:490–500.

5. Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14:1766–73.

6. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008; 19:1727–33.

7. Kulke MH, Shah MH, BensonAB 3rd, et al. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Netw. 2015; 13:78–108.

8. Amin S, Kim MK. Islet cell tumors of the pancreas. Gastroenterol Clin North Am. 2016; 45:83–100.

9. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011; 331:1199–203.

10. Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations. Science. 2011; 333:425.

11. Marinoni I, Kurrer AS, Vassella E, et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. Gastroenterology. 2014; 146:453–60.

12. Kim JY, Brosnan-Cashman JA, An S, et al. Alternative lengthening of telomeres in primary pancreatic neuroendocrine tumors is associated with aggressive clinical behavior and poor survival. Clin Cancer Res. 2017; 23:1598–606.

13. Singhi AD, Liu TC, Roncaioli JL, et al. Alternative lengthening of telomeres and loss of DAXX/ATRX expression predicts metastatic disease and poor survival in patients with pancreatic neuroendocrine Tumors. Clin Cancer Res. 2017; 23:600–9.

14. Kim JY, Kim MS, Kim KS, et al. Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors. Am J Surg Pathol. 2015; 39:592–601.

15. Arnason T, Sapp HL, Barnes PJ, Drewniak M, Abdolell M, Rayson D. Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors. Neuroendocrinology. 2011; 93:249–58.

16. Viale G, Doglioni C, Gambacorta M, Zamboni G, Coggi G, Bordi C. Progesterone receptor immunoreactivity in pancreatic endocrine tumors: an immunocytochemical study of 156 neuroendocrine tumors of the pancreas, gastrointestinal and respiratory tracts, and skin. Cancer. 1992; 70:2268–77.

17. Doglioni C, Gambacorta M, Zamboni G, Coggi G, Viale G. Immunocytochemical localization of progesterone receptors in endocrine cells of the human pancreas. Am J Pathol. 1990; 137:999–1005.

18. Hruban RH, Pitman MB, Klimstra DS. Tumors of the pancreas. Washington, DC: American Registry of Pathology;2007.

19. Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS. Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol. 2012; 36:1761–70.

20. Son EM, Kim JY, An S, et al. Clinical and prognostic significances of cytokeratin 19 and KIT expression in surgically resectable pancreatic neuroendocrine tumors. J Pathol Transl Med. 2015; 49:30–6.

21. Roh J, Knight S, Chung JY, et al. S100A4 expression is a prognostic indicator in small intestine adenocarcinoma. J Clin Pathol. 2014; 67:216–21.

22. Jang KT, Park SM, Basturk O, et al. Clinicopathologic characteristics of 29 invasive carcinomas arising in 178 pancreatic mucinous cystic neoplasms with ovarian-type stroma: implications for management and prognosis. Am J Surg Pathol. 2015; 39:179–87.

23. Anlauf M, Perren A, Klöppel G. Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance. Pathobiology. 2007; 74:279–84.

24. Anlauf M, Schlenger R, Perren A, et al. Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Patho. 2006; 30:560–74.

25. Hackeng WM, Brosens LA, Poruk KE, et al. Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis. Hum Pathol. 2016; 56:93–100.

26. Hirabayashi K, Yamada M, et al. Molecular alterations in sporadic pancreatic neuroendocrine microadenomas. Pancreatology. 2016; 16:411–5.

27. de Wilde RF, Heaphy CM, Maitra A, et al. Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors. Mod Pathol. 2012; 25:1033–9.

28. Estrella JS, Broaddus RR, Mathews A, et al. Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors. Arch Pathol Lab Med. 2014; 138:1027–36.

29. Pelosi G, Bresaola E, Bogina G, et al. Endocrine tumors ofthe pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol. 1996; 27:1124–34.

30. Li X, O'Malley BW. Unfolding the action of progesterone receptors. J Biol Chem. 2003; 278:39261–4.

31. Yazdani S, Ogata H, et al. Progesterone receptorisoforms A and B in pancreatic neuroendocrine tumor. Neuroendocrinology. 2015; 101:309–20.